Loading...
Market
What will be the outcome of ITI-1284 Phase 2 trials for anxiety by end of 2025?
2
Resolution / Starting Odds
Successful trial • 33%
Unsuccessful trial • 33%
Inconclusive results • 34%
Clinical trial results published by Intra-Cellular Therapies or scientific journals
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio with Caplyta
Jan 13, 2025, 12:19 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion in cash, or $132 per share. The deal, announced on the first day of the J.P. Morgan Healthcare Conference, aims to bolster Johnson & Johnson's neuroscience portfolio with Intra-Cellular's Caplyta, a drug approved for treating schizophrenia and bipolar depression. Intra-Cellular recently filed for an expanded approval of Caplyta to treat major depressive disorder, which could significantly increase its market potential. The acquisition also includes ITI-1284, a drug in Phase 2 testing for generalized anxiety disorder and Alzheimer's-related conditions. Johnson & Johnson plans to fund the acquisition through cash on hand and debt, with the deal expected to close later in 2025, subject to regulatory approvals.
View original story
Similar markets
Significant improvement • 25%
Worsening condition • 25%
No improvement • 25%
Moderate improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Positive results leading to Phase 2 • 25%
Other outcome • 25%
Neutral results requiring further study • 25%
Negative results halting development • 25%
Negative results • 25%
Mixed results • 25%
Positive results with MRD-negative CR • 25%
Trial discontinued • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Effective only for PTSD • 25%
Effective for both PTSD and alcohol use disorder • 25%
Not effective for either condition • 25%
Effective only for alcohol use disorder • 25%
No significant results • 25%
Significant positive results • 25%
Moderate positive results • 25%
Negative results • 25%
Negative results • 25%
Positive results • 25%
Trial extended • 25%
Inconclusive results • 25%
Safe but not effective • 25%
Effective but not safe • 25%
Neither safe nor effective • 25%
Safe and effective • 25%
Conditional Approval • 25%
Withdrawn by Axsome • 25%
Rejected • 25%
Approved • 25%